OncoSec Medical Inc (ONCSQ)

[guti]

Low-Dose Ipilimumab/Pembrolizumab reduces toxicity in advanced melanoma.

http://www.cancernetwork.com/smr-2015/low-dose-ipilimumab-pembrolizumab-reduces-toxicity-advanced-melanoma

In conclusion, “The combination of pembrolizumab and low-dose ipilimumab is tolerable, and provided an ORR that is comparable to that previously reported for nivolumab and full-dose ipilimumab.” Efficacy, safety, and biomarkers will be further analyzed in a full expansion cohort of 153 patients. However, let’s keep in mind that both combinations of ipilimumab with nivolumab or with ipilimumab have a high rate of AEs.

In Oncosec's combination trial with ImmunoPulse IL-12, pembrolizumab will be administered at 200mg flat dose every 3 weeks, which means that unless every patient weights an average of 100kg, pembrolizumab will be given at higher rates than the ones being used with the ipilimumab/pembrolizumab combination . And if in fact it lessens drastically the adverse events, while improving results with that slight increase in dosage and incorporation of IL-12, there will be no hesitation in moving forward and using the ImmunoPulse platform in a combination that might already be approved using pembrolizumab.